NYSE: $ABBV Transforming Care for NSCLC Patients In a significant step forward for oncology, AbbVie has announced that the U.S. Food and Drug Administration (FDA) has granted two Breakthrough Therapy Designations (BTD) to their investigational therapy, telisotuzumab vedotin (Teliso-V). This recognition highlights the potential of this treatment to address the urgent needs of patients living…